studies

1262A AASLD ABSTRACTS HEPATOLOGY, October, 2015
hypertension, fasting plasma insulin and vitamin B12. In contrast,
the fibrosis score was higher by 1.4 units in the high
folate group (RBC folate > 620 ng/ml) compared to low folate
group (p=0.003) in patients with the homozygous group. The
fibrosis score increases by 0.06 units for every 25mg increase
in serum folate level in homozygous group (p=0.014). Plasma
vitamin B12 was not associated with histological severity. Conclusions.
While folate has a protective effect on ballooning and
the overall NAS score in NAFLD, in those NAFLD patients with
the MTHFR homozygous mutation high folate levels had more
advanced fibrosis. Despite the reported decreased activity of
mutated MTHFR, folate supplementation may contribute to progression
of fibrosis and should be used with caution.
Disclosures:
The following authors have nothing to disclose: Jaividhya Dasarathy, Rony Varghese,
Iryna Kalinina, Rocio Lopez, Arthur J. McCullough, Srinivasan Dasarathy
2163
The Lipidomic Signature Of Disease Progression In Nonalcoholic
Fatty Liver Disease (NAFLD)
Cristina Alonso 1 , Amon Asgharpour 2 , Ibon Martinez-Arranz 1 ,
Puneet Puri 2 , Mohammad S. Siddiqui 2 , Pablo Ortiz 1 , Jose M.
Mato 3 , Arun J. Sanyal 2 ; 1 OWL, Derio, Spain; 2 VCU Medical Center
Richmond, Division of Gastroenterology and Hepatology, Richmond,
VA; 3 CIC bioGUNE, Ciberehd, Derio, Spain
BACKGROUND:NAFLD includes a spectrum of histological
phenotypes which can progress to cirrhosis at variable rates.
While fibrosis assessment with a liver biopsy is the gold standard
for assessment of disease progression it is limited by
sampling variability and its invasive nature. There is therefore
a major unmet need to identify a signature of disease progression
that does not rely on a liver biopsy. Metabolomics
provides an unbiased approach to obtain an assessment of
whole-body metabolic response to disease progression. Previous
attempts to describe a lipid signature focused on fatty liver
vs.NASH (Hepatol 2009,50:1827, J Prot Res 2012,11:2521,
J Lipid Res 2015,56:185) or NASH vs.cirrhosis (J Lipid Res
2015,56:722). The lipidomic signature of disease progression
over earlier stages remains unknown. AIM:To characterize
the changes in the circulating lipidome with disease
progression from no fibrosis to advanced fibrosis in subjects
with NAFLD. METHODS:Plasma samples collected at the time
of liver biopsy were analyzed by UPLC-MS. Specifically, amino
acids, fatty acyls, bile acids, glycerolipids, glycerophospholipids,
sterols and sphingolipids were analyzed. RESULTS:
11controls, 29NAFLD with no fibrosis, 43NAFLD with early
stage fibrosis (stage1-2) and 22NAFLD with advanced fibrosis
(stage3-4) were studied. 22metabolites were associated
with disease progression (Figure). While cholesteryl esters and
phosphatidylcholines, decreased with the progression [t-test
Control vs.NAFLD with no fibrosis; early stage or advanced
fibrosis: PC(O-24:1/0:0) and PC(18:2/20:4):p